Clinical trial
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic…
NCT00126542 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00126542 |
|---|---|
| Title | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| Official title | A Phase II Trial of Bevacizumab (NSC# 704865) and OSI-774 (NSC# 718781) In Recurrent Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | Apr 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Apr 1, 2010 |
| First posted | Aug 4, 2005 |
| Last update posted | May 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: